What is Precigen's market cap?

Precigen (PGEN) has a market capitalization of $2.0B and trades on NASDAQ.

What is Precigen's revenue and profitability?

Precigen generated $26.6M in trailing twelve-month revenue with a net loss of $204.4M, representing a net margin of -3656.0%. Gross margin stands at 83.6%, with free cash flow of -$117.0M. These figures are based on the Q1 2026 filing.

Who are Precigen's competitors?

Precigen's key competitors include INOVIO Pharmaceuticals, BioNTech SE, Kite Pharma, and others. These companies compete in similar markets and product categories.

Who does Precigen partner with?

Precigen's notable partners include National Cancer Institute, Eversana, University of Texas MD Anderson Cancer Center, and others.

What subsidiaries does Precigen have?

Precigen's subsidiaries include Precigen Exemplar, Precigen ActoBio.

Where is Precigen headquartered?

Precigen is headquartered in United States of America and employs approximately 202 people. It has been publicly traded since 2013.

Precigen

PGEN

Precigen is a commercial-stage biopharmaceutical company focused on developing precision medicines through proprietary synthetic biology technology platforms.

Market cap

$1.97B+250%

Revenue$26.6M+376%

Net income-$204.4M-30.5%

Free cash flow-$117.0M-55.4%

EPS (diluted)-$1.18-111%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$23.3MBeat by $2.4M EPS-$0.02Beat by $0.01

Read the full report

Next report

Aug 11, 2026 (in a month)

Revenue estimate$28.0M

EPS estimate-$0.02

Financials

Q1 2026

Income statement

See full

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

See full

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

See full

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation & ratios

Valuation

See full

Market cap$1.97B+250%

Enterprise value$2.06B+348%

P/S74.2×—

Returns & leverage

See full

Debt / equity4.9×—

Current ratio4.8×+1.3×

Segments

By product

See full

Papzimeos$21.6M—

Competitors

By market cap

Gilead Sciences$167.41B+20.4%

Bristol-Myers Squibb$118.32B+25.1%

Regeneron Pharmaceuticals$70.0B+20.5%

Apogee Therapeutics, Inc.$10.0B+339%

Precigen$2.0B+320%

Allogene Therapeutics$724.8M+186%

Inovio Pharmaceuticals$97.9M+101%

PDS Biotechnology Corporation$43.9M-21.2%

By revenue growth

Precigen+376%

Regeneron Pharmaceuticals+5.9%

Gilead Sciences+3.5%

Bristol-Myers Squibb+1.8%

By net margin

Gilead Sciences30.99%+10.2pp

Regeneron Pharmaceuticals29.65%-2.3pp

Bristol-Myers Squibb15.01%+3.8pp

Precigen-3,655.99%+2,037pp

Allogene Therapeutics-1,170,863.64%—

Profile

Precigen is a commercial-stage biopharmaceutical company focused on developing precision medicines through proprietary synthetic biology technology platforms. The company specializes in gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, utilizing a decentralized manufacturing model to improve patient access and reduce costs. Its core value proposition lies in its ability to precisely control gene expression and streamline the production of complex biological therapies.

Competitive position

Precigen is a pioneer in decentralized CAR-T manufacturing and holds the first FDA-approved therapy for recurrent respiratory papillomatosis in adults.

GeographiesUnited States, European Union

Customer segmentsPatients, Healthcare Providers, Research Institutions

Business modelProduct-based, Research and Development, Manufacturing-as-a-Service

SuppliersGenetic component suppliers, Laboratory equipment providers, Clinical trial sites, Contract manufacturing organizations

CustomersSpecialty pharmacies, Hospitals, Integrated Delivery Networks, Government health programs, Private health insurers

CountryUnited States of America

Listed2013

Employees202.0

CEOHelen Sabzevari

SectorHealthcare

IndustryBiotechnology

Websiteprecigen.com

FilingsSEC EDGAR

Ask your AI about Precigen.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Precigen's market cap?: Precigen (PGEN) has a market capitalization of $2.0B and trades on NASDAQ.
What is Precigen's revenue and profitability?: Precigen generated $26.6M in trailing twelve-month revenue with a net loss of $204.4M, representing a net margin of -3656.0%. Gross margin stands at 83.6%, with free cash flow of -$117.0M. These figures are based on the Q1 2026 filing.
Who are Precigen's competitors?: Precigen's key competitors include INOVIO Pharmaceuticals, BioNTech SE, Kite Pharma, and others. These companies compete in similar markets and product categories.
Who does Precigen partner with?: Precigen's notable partners include National Cancer Institute, Eversana, University of Texas MD Anderson Cancer Center, and others.
What subsidiaries does Precigen have?: Precigen's subsidiaries include Precigen Exemplar, Precigen ActoBio.
Where is Precigen headquartered?: Precigen is headquartered in United States of America and employs approximately 202 people. It has been publicly traded since 2013.